Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Discontinued Operations: 2021-2022

Historic Cash from Discontinued Operations for Theravance Biopharma (TBPH) over the last 1 years, with Dec 2022 value amounting to -$179.0 million.

  • Theravance Biopharma's Cash from Discontinued Operations fell 6455.40% to -$179.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$184.6 million, marking a year-over-year change of. This contributed to the annual value of -$184.6 million for FY2022, which is 761.12% down from last year.
  • Per Theravance Biopharma's latest filing, its Cash from Discontinued Operations stood at -$179.0 million for Q4 2022, which was down 3,335.75% from -$5.2 million recorded in Q3 2022.
  • In the past 5 years, Theravance Biopharma's Cash from Discontinued Operations registered a high of $2.8 million during Q4 2021, and its lowest value of -$179.0 million during Q4 2022.
  • Its 2-year average for Cash from Discontinued Operations is -$36.4 million, with a median of -$1.0 million in 2022.
  • Data for Theravance Biopharma's Cash from Discontinued Operations shows a maximum YoY tumbled of 6,455.40% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Theravance Biopharma's Cash from Discontinued Operations stood at $2.8 million in 2021, then slumped by 6,455.40% to -$179.0 million in 2022.
  • Its last three reported values are -$179.0 million in Q4 2022, -$5.2 million for Q3 2022, and -$1.0 million during Q2 2022.